Correlation between Apoptotic and Anti-apoptotic Proteins (caspase-3 and Bcl2) in Chronic Hepatitis C: An Immunohistochemical Study

Size: px
Start display at page:

Download "Correlation between Apoptotic and Anti-apoptotic Proteins (caspase-3 and Bcl2) in Chronic Hepatitis C: An Immunohistochemical Study"

Transcription

1 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October Correlation between Apoptotic and Anti-apoptotic Proteins (caspase-3 and Bcl2) in Chronic Hepatitis C: An Immunohistochemical Study Samia El-Naggar and Sahar Aly Daoud Pathology department, Faculty of medicine, Beni -Sueif University, Egypt ABSTRACT There is increasing evidence suggesting that liver cell damage in chronic HCV infection is mediated by induction of apoptosis. The morphological alterations of apoptosis are mediated by a family of intracellular proteases called caspases. Caspase- 3 is the central executioner of many if not all apoptosis pathway. The aim of the work of the present study is to analyze the apoptotic like protein caspase-3 and anti-apoptotic Bcl2 expression in tissues from patients with chronic HCV to throw more light on apoptotic process and their correlation with histopathological changes. Material and Methods: Liver biopsies from 73 patients with chronic HCV (40 patients with history of bilharziasis, 33 patients with no history of bilharziasis) selected from those referred to tropical medicine department, Beni Sueif University hospital before taking treatment, examined by H&E and immunostained for caspase-3 and Bcl2. Results: There was positive correlation between caspase-3 and the grade of activity; as well as the stage of fibrosis in cases with HCV of both groups (those associated and not associated with bilharziasis). While, Bcl2 was not expressed by liver cells. Conclusion: Finding that the anti-apoptotic protein Bcl2 was not expressed in hepatocytes in patients with chronic hepatitis C selected for our study leads to the conclusion that in these cells apoptosis is not inhibited by this protein, fact that could explain the increased apoptosis observed in liver samples from these patients. In addition caspase-3 is a noninvasive measure for detection of early liver cell injury and fibrosis. INTRODUCTION In the last years, infection with hepatitis C virus is prevalent around the world and for more than 80% of cases leads to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. (Tran, 2008) There is a great degree of variation in the prevalence, ranging from less 1% in the United Kingdom to more than 20% in Egypt. In the developed world, the relatively low incidence is mostly due to intravenous drug abuse, while the World Health Organization (WHO) anti- Schistosomal vaccination program in Egypt 1970s and other vaccination programs in Mongolia and Bolivia have led to much higher rate in those countries.(frank, et al., 2000) These figure are alarming, since patients currently asymptomatic with relatively mild disease will eventually progress to end stage liver disease and develop hepatocellular carcinoma (HCC).Moreover, there is no proper vaccine against HCV and anti-viral treatment is not only expensive but relatively toxic, sufficiently ineffective in treating all patients. (Pearlman, 2004) This underscores the need for more effective therapies. A better understanding of the mechanism underlying the pathology of the chronic HCV infection could be helpful in identifying a novel therapeutic target against this disease. The mechanisms by which liver cell inflammation, fibrosis and sign for chronic hepatitis appear are not completely understood. Many studies suggest that apoptosis may be involved in the pathogenesis of chronic hepatitis C. (Bantel and Schultze-Osthoff, 2003), (Fisher et al, 2007). Apoptosis is a complex phenomenon that occurs through two main pathways: extrinsic (mediated by death receptors) and intrinsic (mitochondrial pathway) that converged to final common way involving activation of caspases.(hengartner, 2000 and Gupta, 2003) The intrinsic pathway of apoptosis is initiated within the cell mitochondria; playing an important role. The instability of the mitochondrial membrane induces the release of proapoptotic factors into cytosl, such as cytochrome C, leading to activation of downstream caspases; enzymes responsible for degradation of several cellular changes that define apoptotic cell death. Several intracellular proteins are involved in the regulation of apoptosis constitute the caspase family and in

2 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October particular, the Bcl-2 family of proteins, which includes both pro- and antiapoptotic members; are perhaps the most important regulators of the intrinsic pathway. These proteins act upstream and at the level of the mitochondria to integrate death and survival signals, and the balance between pro- and antiapoptotic members of the family, as well as their reciprocal interactions, determines whether or not the intrinsic pathway of apoptosis is initiated.(garrido et al, 2006 and Rasola, 2007) Aim of the work The aim of the present work is to analyze the apoptotic like protein caspase-3 and antiapoptotic Bcl2 expression in tissues from patients with chronic HCV to throw more light on apoptotic process and their correlation with histopathological changes. MATERIAL & METHODS The current study was carried on 73 patients with chronic HCV selected from those referred to tropical medicine department, Beni Sueif University hospital before taking treatment. Patients with co-infection of other viruses such as HBV, HDV, HIV infection, patients using hepatotoxic drugs, herbal medication within 6 months prior to liver biopsy, patients having diabetes mellitus or hyperlipidemia were excluded. Demographic data (age, gender, and clinical symptoms), biochemical data (aspartate aminotransferase AST, ALT) and serological findings as viral load were recorded. Two pathologists reviewed liver biopsies. Cases were divided into two groups: Group I: Included 40 HCV with history of schistosomiasis. Group II: included 33 HCV with no history of schistosomiasis. Liver biopsies were included in paraffin, processed and cut at 3 µm sections were used for Hematoxylin and Eosin (H&E) stains for histopathological diagnosis, Masson trichrome stain for detection of fibrosis and other sections were fixed on adhesive slide for immunohistochemical staining. Examination of sections stained with Hematoxylin and Eosin (H&E): Several histological features were evaluated as follows: Histological grading of necroinflammatory score based on modified HAI grading by Ishak et al.,(1995) including interface hepatitis (0-4), focal spotty necrosis (0-4), confluent necrosis (0-6) and portal inflammation (0-4). Grades of activity 1-3 were considered minimal, grades 4-8 were considered mild, grades 9-12 were considered moderate and grades were considered severe. Degree of steatosis 0: absent 1 : < 33% 2: 33-66% 3: > 66 Presence of portal lymphoid follicles, presence of bile duct damage (lymphocytic intraepithelial or periductuler infiltration), the involvement pattern in each portal tract ( total involvement > 80%, partial involvement < 80% or no involvement) the knodell histology activity index and fibrosis score of Ishak modified HAI.(Ishak 1995) were also evaluated. Histological staging of fibrosis of chronic hepatitis was done according to fibrosis score (0-6). (Ishak et al.,1995) Immunohistochemical staining for caspase-3 and Bcl2 was performed using the following primary antibodies: polyclonal rabbit caspase-3 diluted (1:50) and monoclonal mouse anti-bcl2, diluted 1:75 (Dako) followed by incubation with appropriate secondary antibody. We use avidinbiotin-peroxidase complex (Vector laboratories) to amplify the reactions and 3, 3'- diaminobenzidine hydrochloride/h2o2 (Sigma Aldrich Co.) to develop them. Nuclear counterstaining was done with Meyer's hematoxylin. The expression of caspase-3 was measured in 10 successive high power fields (x400). It was expressed as brown coloration in hepatocyte cytoplasm. The degree of caspase-3 expression within the hepatic lobules was evaluated semiquantitatively according to the percentage of positively stained cells and classified into four groups. (-)= no immunostaining, (+) = (<25%of cells), (++) = (25%-50cells), (+++) = (>50%- 75% of cells), (++++) =>75%of cells. (Bantel et al 2001). Positive immunostaining expression of Bcl2 was considered if brownish granules in the cytoplasm or in the nucleus of different cells were expressed. A semi-quantitative analysis was

3 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October performed after examination of five microscopic fields (X400) on each slide, assignment of scores, based on the number of positive cells identified. The score was +: up to 5 positive hepatocyte per field, ++: 5-10 positive hepatocytes per field.(borner 2003) Statistical analysis was performed using windows soft ware. The relation was obtained by Pearson Chi- square test. P value less than 0.05 was considered significant. RESULTS According to age of the present studied cases; mean age in group I was 43y and group II was 48y. As regards sex distribution: male to female ratio in group I was 2:1 and 3:2 in group II, the difference between groups of patients in age and sex distribution was statistically insignificant (P= and P= 0.086) respectively. Histological examination of liver biopsies done on group I revealed minimal activity in 10 cases, mild activity in 7 cases, moderate activity in 11 cases, severe activity in 12 cases. As regard group II: we found minimal activity in 3 cases, mild activity in 10 cases, moderate activity in 5 cases, severe activity in 15 cases. <5% steatosis was found in 18 cases(45%) in group I and 13 cases(39%) in group II. Immunohistochemical stains for detection of caspase-3 and Bcl2: Expression of the two apoptotic protein caspase- 3 and Bcl2, which are involved in apoptosis execution and anti-apoptotic function, respectively, were assessed. There was no significant correlation between Caspase-3 with any of the histological features. Immunohistochemical assessment of caspase-3 and activity in liver biopsy specimens was shown in (table1): The grading of caspase-3 activity was expressed as percentage of positively stained cells. Minimal activity was found in (25%). Mild activity was found in (17.5%), moderate activity was found in 27.5%, marked activity was found in (30%) of liver biopsy in group I. In group II, minimal activity was found in 9.1% of cases. Mild activity was found in 30.3% of cases, moderate activity was found in 15% of cases. Severe activity was found in 45.6% of cases (fig: 1 a,b,c,d), P value < 0.05 for each, however there was no significant correlation between both groups (P value = 0.099). Table (1): correlation between caspase-3 immunostaining and grade of hepatitis activity in liver biopsy of studied cases Caspase-3 immunostaining Grade of Hepatic activity Group I(n=40) n (%) Group II ( n33) n (%) Minimal 10 (25%) 3 (9.1 %) Mild 7 (17.5%) 10 (30.3%) Moderate 11 (27.5%) 5 (15 %) Severe 12(30%) 15 (45.6%) X2 P Chi-Square: P- value 0.099

4 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October A B C D Figure 1: Liver biopsy of HCV showed mild activity in group I (H&E X100) (a), the hepatocytes were positive for caspase-3 immunostaining; 75% of cells were scored +++ (b). Liver biopsy of HCV showing mild activity in group II (H&E X200) (c), 50 % of hepatocytes were positive for caspase 3 scored as ++ (x400) (d). Fibrosis of different stages 0-6 was diagnosed by Masson trichrome stain. The relation between caspase-3 and the stage of fibrosis was tabulated in table 2. It was notable that caspase-3 was expressed more in cases with fibrosis stages 4, 5 and 6 in both groups (statistically insignificant p value > 0.05) (fig:2 a,b). Table (2): correlation between caspase-3 immunostaining and stage of fibrosis in liver biopsy of studied cases Caspase-3 immunostaining Group I(n=40) n (%) Group II ( n33) n (%) Stage of fibrosis 0 1 ( 2.5 % ) 3 (9.1 %) 1 6 ( 15 % ) 5 ( 15.1%) 2 3 ( 7.5 %) 4 ( 12.2%) 3 8 ( 20%) 4 ( 12.2%) 4 5 (12.5%) 5 (15.1%) 5 9 ( 22.5%) 7 ( 21.2%) 6 8 ( 20%) 5 ( 15.1%) X2 P Chi-Square: P- value Hepatocytes didn't reveal positivity for Bcl2.We noted Bcl2 positive cells in the areas of inflammatory infiltrate, these cells being most likely lymphocytes (fig 2, c)

5 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October A B C Figure 2: Liver biopsy of HCV, showing cirrhosis (stage 6) (masson trichrome X200), the hepatocytes showed positive caspase-3 immunostaining score++++ (X400) (b), negative immunoreaction for bcl2, the inflammatory cells were positive (X400) (c). DISCUSSION Hepatitis C viral infection is a major cause of liver disease, characterized by inflammation, cell damage and fibrotic reaction of hepatocytes.there is increasing evidence suggesting that liver cell damage in chronic HCV infection is mediated by induction of apoptosis. (Bantel and Schulze-Osthoff., (2003) The morphological alterations of apoptosis are mediated by a family of intracellular proteases called caspases.(los et al., 1999) Caspase- 3 is the central executioner of many if not all apoptosis pathway. (Van Molle et al. (1999) In the present study apoptosis could not be seen by H&E Stains. By immunohistochemistry caspase- 3 activity in liver tissue was detected as brown stains in cell cytoplasm of chronic HCV liver tissue with positive correlation to the grade of activity; regardless the intensity of the stain. These finding were in agreement with previous studies by Ibrahim (2004) who obtained a direct evidence for variable degree of liver cell apoptosis in the liver of patients with chronic HCV and a significant correlation was found between the amount of apoptosis, expressed as apoptotic index and inflammatory activity in the liver. Also the results of the present study are in agreement with Bantel et al, (2001) who found that liver cell damage in chronic HCV infection is mediated by induction of apoptosis. Caspases are activated in human biopsy specimens of chronic hepatitis patients, activation of Caspase- 3 correlated significantly with inflammatory activity. Similar results were also found by Bantel et al., (2004) who found that chronic HCV infection is characterized by massive caspase activation, hepatocytes exhibiting immunoreactivity for active caspases and apoptotic features. So, they suggested that measurement of caspase-3 activation may be a suitable marker for detecting very early signs of liver damage. Although the pattern of HCV/schistosomal infection frequent in many geographic areas previous reports showed more severe liver disease in co-infected patients, the inter-actions between HCV and schistosomal infection are not fully understood.(kamal et al.,2000) In the present study, no significant difference was found between co-infected patients in group I and mono- infected patients in group II as regard liver disease severity. This was in agreement with Blanton et al., (2002) study in Egypt, who found that there was no interaction between schistosomal infection or disease and the prevalence and severity of hepatitis C. For both infections, the intensity or prevalence of infections was a poor predictor of morbidity. The prevalence of chronic liver disease in the Egyptian population from different pathogens suggests a generalized susceptibility to inflammatory liver disease. In the present study caspase-3 was expressed with higher stages of fibrosis (4, 5, and 6) with slight higher incidence in cases associated of schistosomiasis statistically insignificant. Anglico et al., (1997) and Kamal et al., (2000) stated that patients with concomitant schistosoma and HCV infection have higher incidence of cirrhosis and hepato-cellular carcinoma than patients with chronic HCV mono-infection, matched for age, disease duration, and HCV genotype. Kamal et al., (2000) found that, fibrosis was significantly accelerated in co-infected patients than mono-

6 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October infected patients and explained the cause of fibrosis progression by additive effects of 2 injurious agents or the difference in immune response and alteration of host signaling pathway inflicted by schistosomal infection, resulting in fibrogenesis. The results of the current study may be explained on the basis of the small number of the studied cases. The effect of co-infection of HCV and Schistosomiasis need long term follow up, which is not included in the current study. Repeated courses of antischistosomal therapy which is a very common attitude in Egyptians may greatly diminish the effect of schistosomal infection. As regards immunoreactivity for Bcl2 in liver biopsies taken from patients with chronic hepatitis C from both groups I and II, hepatocytes didn't reveal positivity for Bcl2. We noted Bcl2 positive cells in the areas of inflammatory infiltrate, these cells being most likely lymphocytes. Several studies have shown that proteins of the Bcl2 family are important regulators of apoptosis. They integrate various signals for survival or cell death generated within or outside the cells, the reaction between pro-and anti-apoptotic members of this family setting limits that cause cell death or survival. (Burlacu, 2003 and Borner, 2003) Our results regarding the expression of Bcl2 protein are consistent with those obtained in other studies which have revealed that this protein is not expressed or have negligible expression in hepatocytes in patients with hepatitis (Tsamandas et al., 2003 and Sarfraz et al., 2008), but in contradiction with those studies saying that Bcl2 is expressed in the cytoplasm of hepatocytes in chronic liver disease. (Chen et al., 2004) Conclusion: Caspase-3 is a noninvasive measure for detection of early liver cell injury and fibrosis.finding that the anti-apoptotic protein Bcl2 was not expressed in hepatocytes in patients with chronic hepatitis C leads to the conclusion that apoptosis is not inhibited by this protein, fact that could explain the increased apoptosis observed in liver samples from these patients. REFERENCES 1. Angelico ME, Rengansthan CG, Gandin, et al., (1997): Chronic liver disease in the Alexandria governorate, Egypt contribution of schistosomiasis and hepatitis virus infection. J Hepatology; 26: Bantel H., Lugering A., Porembo C. (2001): Caspase activation correlated with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology; 34 (4): Bantel H., Schultze-Osthoff K. (2003): Apoptosis in hepatitis C virus infection. Cell death diff; 10: Bantel H., Lugering A., Heidemann I., et al., (2004): Detection of apoptosis caspases activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology; 40: Blanton R.E., Salam E.A., Katiuki H.C., et al., (2002): Population- based difference in schistosomsa- mansoni and hepatitis C induced disease. J Infect Dis ;185 (11) : Borner C. (2003): The Bcl-2 protein family: sensors and checkpoints for lifeor-death decision. Mol.Immunol; 39: Burlacu A. (2003): Regulation of apoptosis by Bcl-2family proteins. J.Cell.Mol. Med; 7(3): Chen N.L.,Bai L., Chen P.l.,Zhang, Ch., et al., (2004): Apoptosis pathways of liver cells in chronic hepatitis.world J.Gastroentrol; 10 (21): Fisher R., Baumert Th., Blum H. (2007): Hepatitis C viral infection and apoptosis. World J.Gastroentrol; 13 (36): Frank C., Mohamed M.K., Strickland K.T., et al., (2000): The role of parenteral anti-schitosomal therapy in the spread of HCV in Egypt. Lancet;355: Garrido C., Galluzzi L., Brunet M., Puig P.E., et al.,(2006): Mechanism of cytochrome c release from mitochondria. Cell death diff ;13: Gupta S. (2003): Molecular signaling in death receptor and mitochondrial pathways of apoptosis.int. J. Oncol;

7 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October : Hengartner M. (2000): Biochemistry of apoptosis. Nature; 407: Ibrahim R. (2004): Liver cell apoptosis in Egyptian patients with chronic hepatitis C.M D thesis.cairo University. 15. Kamal S. M., Madwar M. A., Peter T., et al., (2000): Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatology; 32: Los M., Wesslbong S., Schulez-Osthoffk (1999): The role of caspases in development, immunity and apoptotic signal transduction lessons from knockout mice.immunity;10: Pearlman B.L. (2004): Heaptitis C infection: a clinical review. South Med J, 97(4) Rasola A., Bernardi P. (2007): The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis., Tran G. (2008): The role of hepatitis C virus in the pathogenesis of hepatocellular carcinoma. Bioscince Hrizons;1(2): Tsamandas A.C., Thomopoulos C., Zolota V., Kourelis Th., et al., (2003): Potential role of Bcl-2 and Bax mrna and protein expression in chronic hepatitis type B and C ;A clinico,pathological study. Mol.Path; 16 (12): Van Mole W., Deecker G., Rodriguez I., et al., (1999): Activation of caspases in lethal experimental hepatitis and prevention by acute phase protein.j Immunol; 163:

8 KASR EL AINI MEDICAL JOURNAL VOL. 17, NO 3, October

"Lucian Blaga"University Sibiu Faculty of Medicine Victor Papilian. EVALUATION OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C. PhD thesis abstract

Lucian BlagaUniversity Sibiu Faculty of Medicine Victor Papilian. EVALUATION OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C. PhD thesis abstract "Lucian Blaga"University Sibiu Faculty of Medicine Victor Papilian EVALUATION OF LIVER FIBROSIS IN CHRONIC VIRAL HEPATITIS C. PhD thesis abstract Scientific coordinator Prof. Dr. Mircea DEAC PhD student

More information

Hepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?

Hepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm? Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History

More information

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Molecular Diagnosis of Hepatitis B and Hepatitis D infections Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication

More information

Liver Disease and Therapy of Hepatitis B Virus Infections

Liver Disease and Therapy of Hepatitis B Virus Infections Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin

More information

Transmission of HCV in the United States (CDC estimate)

Transmission of HCV in the United States (CDC estimate) Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

More information

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

BACKGROUND MEDIA INFORMATION Fast facts about liver disease BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of

More information

The Epidemiology of Hepatitis A, B, and C

The Epidemiology of Hepatitis A, B, and C The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations

More information

HCV Treatment Failure

HCV Treatment Failure بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com

More information

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Viral Hepatitis Case Report

Viral Hepatitis Case Report Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date

More information

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf

More information

Ishak versus METAVIR: Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C

Ishak versus METAVIR: Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C 10 Ishak versus METAVIR: Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C Gamal Shiha and Khaled Zalata Internal medicine department & pathology department, Mansoura

More information

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient

More information

OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS C A CLINICAL STUDY

OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS C A CLINICAL STUDY OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS C A CLINICAL STUDY By Prof. Dr. Mohamed Nabil Mawsouf*, **, Dr. Taha Tarek Tanbouli**& Dr.Wagdy Ibrahim El-Tayar** * Cancer Institute, Cairo University **

More information

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for

More information

HEPATITIS COINFECTIONS

HEPATITIS COINFECTIONS HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)

More information

Cirrhosis and HCV. Jonathan Israel M.D.

Cirrhosis and HCV. Jonathan Israel M.D. Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment

More information

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function

More information

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

Albumin. Prothrombin time. Total protein

Albumin. Prothrombin time. Total protein Hepatitis C Fact Sheet February 2016 www.hepatitis.va.gov Laboratory Tests and Hepatitis If you have hepatitis C, your doctor will use laboratory tests to about learn more about your individual hepatitis

More information

Autoimmunity and immunemediated. FOCiS. Lecture outline

Autoimmunity and immunemediated. FOCiS. Lecture outline 1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic

More information

Alanine aminotransferase (serum, plasma)

Alanine aminotransferase (serum, plasma) Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase

More information

HBV DNA < monitoring interferon Rx

HBV DNA < monitoring interferon Rx Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute

More information

HIGHLIGHTS FROM THE AASLD MEETING. Rob Goldin. Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk

HIGHLIGHTS FROM THE AASLD MEETING. Rob Goldin. Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk HIGHLIGHTS FROM THE AASLD MEETING Rob Goldin Imperial College Faculty of Medicine at St Mary s r.goldin@imperial.ac.uk What was on at the meeting? 1. Postgraduate Course 2. Oral Presentations 3. Poster

More information

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex

More information

2015 Outpatient Chronic Hepatitis B Management

2015 Outpatient Chronic Hepatitis B Management 2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis

More information

New IDSA/AASLD Guidelines for Hepatitis C

New IDSA/AASLD Guidelines for Hepatitis C NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation

More information

Notch 1 -dependent regulation of cell fate in colorectal cancer

Notch 1 -dependent regulation of cell fate in colorectal cancer Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1

More information

Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases

Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases M. Trauner, Division of Gastroenterology and Hepatology, Department of Internal Medicine, MUG Co- Investigator: H. Samonigg,

More information

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio

More information

Viral Hepatitis. 2009 APHL survey report

Viral Hepatitis. 2009 APHL survey report Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories

More information

Update on Hepatitis C. Sally Williams MD

Update on Hepatitis C. Sally Williams MD Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi

More information

Antioxidant response in patients with chronic hepatitis B or C.

Antioxidant response in patients with chronic hepatitis B or C. Antioxidant response in patients with chronic hepatitis B or C. Kamila Wójcik, Anna Piekarska, Elżbieta Jabłonowska Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland

More information

2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements

2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase

More information

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment

More information

The Natural History of Chronic Hepatitis B Virus Infection

The Natural History of Chronic Hepatitis B Virus Infection The Natural History of Chronic Hepatitis B Virus Infection Brian J. McMahon, M.D. 1 ABSTRACT Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic

More information

Hepatitis C Infections in Oregon September 2014

Hepatitis C Infections in Oregon September 2014 Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with

More information

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,

More information

Knowledge about Post-exposure Prophylaxis for Hepatitis B Virus among Dentists and Dental Students in Pakistan

Knowledge about Post-exposure Prophylaxis for Hepatitis B Virus among Dentists and Dental Students in Pakistan {189} ORIGINAL RESEARCH Knowledge about Post-exposure Prophylaxis for Hepatitis B Virus among Dentists and Dental Students in Pakistan Zohaib Ahmed 1 Umber Zahra 2 Nasir Saleem 3 1,2 BDS. House Officer.

More information

Co-infected health-care workers

Co-infected health-care workers Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care

More information

Review: How to work up your patient with Hepatitis C

Review: How to work up your patient with Hepatitis C Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.

More information

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center

More information

Management of Chronic Hepatitis B: 2012 Update

Management of Chronic Hepatitis B: 2012 Update Management of Chronic Hepatitis B: 2012 Update Brian J McMahon MD, Liver Disease and Hepatitis Program Alaska Native Medical Center and Arctic Investigations Program, CDC Conflicts of Interest The Liver

More information

Comparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases

Comparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases Available online at wwwpelagiaresearchlibrarycom European Journal of Experimental Biology, 2013, 3(2):280-284 ISSN: 2248 9215 CODEN (USA): EJEBAU Comparative Levels of ALT, AST, ALP and GGT in Liver associated

More information

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models

More information

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission

More information

INFORMATION ABOUT HEPATITIS C

INFORMATION ABOUT HEPATITIS C INFORMATION ABOUT HEPATITIS C PATIENT BOOKLET Index 1 About Hepatitis C About Hepatitis C Page 1 Hepatitis C Transmission Page 3 Hepatitis C Disease Progression Page 4 Hepatitis C Diagnosis and Treatment

More information

3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.

3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300. April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the

More information

Treatment of Acute Hepatitis C

Treatment of Acute Hepatitis C Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common

More information

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune

More information

General presentation

General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology (NIRDMIC)

More information

Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice

Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Dr Chris Ford GP & SMMGP Clinical Lead Kate Halliday Telford & Wrekin Shared Care Coordinator Aims Discuss:

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations

HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic

More information

Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D.

Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D. Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China Title Charles Wang, M.D. Background Hepatitis C infects 170 million worldwide & 3 million Chinese HIV infects 33.3 million worldwide & 740,000

More information

Indications in Hepatology and Liver Diseases

Indications in Hepatology and Liver Diseases exclusively working in Health Care sananet GmbH Tilo Stolzke Breite Str. 6-8 23562 Lübeck Germany Telefon : +49 451 400 8301 Telefax : +49 451 400 8302 E-Mail : stolzke@sananet.com Internet : www.sananet.com

More information

BURDEN OF LIVER DISEASE IN BRAZIL

BURDEN OF LIVER DISEASE IN BRAZIL BURDEN OF LIVER DISEASE IN BRAZIL Burden of Liver Disease in Europe Blachier et al. J Hepatol 58:593, 2013 Review of 260 epidemiologic studies of the 5 previous years Cirrhosis is responsible for 170.000

More information

Hepatitis C - genotype 2/3

Hepatitis C - genotype 2/3 Hepatitis C - genotype 2/3 Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other

More information

Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model

Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model J Clin Pathol 1996;49:465-469 Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model 465 V S Wong, D G D Wight, C R Palmer, G J M Alexander Department of Medicine,

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

Microarray analysis of viral infections

Microarray analysis of viral infections Microarray analysis of viral infections Dipl. Biol. Department of Virology Bernhard Nocht Institute for Tropical Medicine Berhard Nocht Institut für Tropenmedizin Possible investigations of viral infections

More information

Conveners: S. Bruno, C.M. Mastroianni

Conveners: S. Bruno, C.M. Mastroianni SESSIONE 2 Oral communications based on selected abstracts Conveners: S. Bruno, C.M. Mastroianni PNPLA3 variant is an independent predictor of severe steatosis in patients with chronic hepatitis C and

More information

Approach to Abnormal Liver Tests

Approach to Abnormal Liver Tests Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School

More information

CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA

CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA WHAT IS CANCER OF THE LIVER? Hepatocellular carcinoma is the most common form and it comes from the main type of liver cell, the hepatocyte. About 3 out 4

More information

Immunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany

Immunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany Services & Products Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany Phone Europe: +49-40-41 33 83-0 Fax Europe: +49-40-41 33 83-14 Phone USA: +1-301-588-4650 info@indivumed.com www.indivumed.com

More information

HEPATITIS C. The Facts. Get Tested. Get Cured! Health

HEPATITIS C. The Facts. Get Tested. Get Cured! Health HEPATITIS C The Facts Get Tested. Get Cured! Health EVEN IF YOU FEEL HEALTHY, HEPATITIS C MAY BE DAMAGING YOUR LIVER. Your liver keeps you healthy in many ways, such as by removing toxins from your blood

More information

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease

Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease Liver pathology and HCV genotype 53 ORIGINAL ARTICLE Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease Rachel Abraham Banumathi Ramakrishna

More information

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence

More information

The immunogenic vaccine against HCV and HBV

The immunogenic vaccine against HCV and HBV National Centre for Research and Development, The immunogenic vaccine against HCV and HBV Katarzyna Grzyb Laboratory of Virus Molecular Biology Intercollegate Faculty of Biotechnology UG-MUG 1 Hepatitis

More information

Hepatitis C. Laboratory Tests and Hepatitis C

Hepatitis C. Laboratory Tests and Hepatitis C Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what

More information

Disclosure of Conflicts of Interest Learner Assurance Statement:

Disclosure of Conflicts of Interest Learner Assurance Statement: Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation

More information

UCLA Asian Liver Program

UCLA Asian Liver Program CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,

More information

PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN?

PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN? PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN? John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology

More information

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta

More information

Sovaldi (sofosbuvir) Prior Authorization Criteria

Sovaldi (sofosbuvir) Prior Authorization Criteria INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant

More information

EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version)

EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version) Journal of Hepatology 38 (2003) 533 540 Special article EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version) The EASL Jury*

More information

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide Newly Diagnosed: HEPATITIS C American Liver Foundation Support Guide T he American Liver Foundation's mission is to facilitate, advocate, and promote education, support, and research for the prevention,

More information

Chronic Hepatitis C in Northern India - The Pathological and Clinical Spectrum

Chronic Hepatitis C in Northern India - The Pathological and Clinical Spectrum Original Article Chronic Hepatitis C in Northern India - The Pathological and Clinical Spectrum A Sood*, Vandana Midha**, Neena Sood***, Harpreet Kaur***, Vineeta Malhotra***, G Awasthi** Abstract Background

More information

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000

More information

Bottlenecks in Clinical Source Material Acquisition. Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.

Bottlenecks in Clinical Source Material Acquisition. Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions. Bottlenecks in Clinical Source Material Acquisition Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.com Biopreservation What s the issue? Biopreservation considerations

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

Psoriasis; a new marker for Hepatitis C among Egyptian Patients

Psoriasis; a new marker for Hepatitis C among Egyptian Patients ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 761-767 http://www.ijcmas.com Original Research Article Psoriasis; a new marker for Hepatitis C among Egyptian Patients Asmaa E Mohamed 1, Samaa A Taha 2, Amal

More information

Update on hepatitis C: treatment and care and future directions

Update on hepatitis C: treatment and care and future directions Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New

More information

Drugs Believed Capable of Inducing Autoimmune Hepatitis

Drugs Believed Capable of Inducing Autoimmune Hepatitis Drugs Believed Capable of Inducing Autoimmune Hepatitis Leonard B. Seeff, M.D. National Institutes of Diabetes and Digestive and Kidney Diseases National Institutes of Health Immune-Mediated Liver Diseases

More information

LIVER FUNCTION TESTS AND STATINS

LIVER FUNCTION TESTS AND STATINS LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated

More information

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH

More information

National Health Burden of CLD in Italy

National Health Burden of CLD in Italy National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /

More information

Living with HEP C. Facts about Hepatitis C

Living with HEP C. Facts about Hepatitis C Living with HEP C Facts about Hepatitis C IMPORTANT The information in this booklet is intended for people who are newly diagnosed with Hepatitis C (called Hep C for short). It can help you learn more

More information

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US

More information

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common

More information

New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head

New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head New Approaches to a Major Public-Health Problem Infectious Diseases Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head Overview The Burden Of Infectious Disease Is Large And May

More information

Non Alcoholic Steato-Hepatitis (NASH)

Non Alcoholic Steato-Hepatitis (NASH) Non Alcoholic Steato-Hepatitis (NASH) DISCLAIMER NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY AND OR DAMAGE TO PERSONS OR PROPERTY ARISING FROM THIS WEBSITE AND ITS CONTENT.

More information

Summary & Conclusion

Summary & Conclusion The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with

More information